RAD51 was also shown to be a marker of resistance to PARPi in BRCA-mutated breast cancer,34 and depletion of RAD51 via RNAi could re-sensitize cancer cells to PARP inhibition.35 This evidence concerns the gene RAD51 and breast cancer.